Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Segezha will decide on the construction of a new pulp and paper mill in Karelia not before 2025

2/17/23 SGZH

RusHydro's 2022 RAS profit halved

2/17/23 HYDR

VK sells R_keeper restaurant platform

2/17/23 VKCO

Gazprom is excluded from increased income tax on LNG exports

2/17/23 GAZP

Bulgaria fined Lukoil €34.6 million for price pressure

2/17/23 LKOH

Drones can cut operating costs by 37%

2/17/23 SIBN

Unipro's profit in 2022 increased 2.6 times

2/17/23 UPRO

Maxim Berlovich and Oleg Mubarakshin resigned from Board of Directors of Etalon

2/17/23 ETLN

NLMK is looking for a buyer for its long product division

2/17/23 NLMK

Germany intends to simplify the sale of Rosneft's stake in the Schwedt refinery

2/17/23 ROSN